KUALA LUMPUR – Bintai Kinden Corporation Bhd’s partner, Generex Biotechnology Corporation, has signed a framework agreement for the development and commercialisation of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.
The agreement was signed with the Chinese Centre for Disease Control and Prevention (China CDC), Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co Ltd.
In a statement today, Bintai Kinden said under the agreement, Generex would receive upfront development fees and back-end licensing payments, while the partners would undertake research and development and pay 100% of the funding required for the vaccine's commercial approval of the Ii-Key-CoV-2 vaccine.
This includes laboratory work, manufacturing, regulatory filings, and the clinical development programme for regulatory approval of the vaccine in China.
The Ii-Key-SARS-CoV-2 vaccine was designed as a “complete vaccine” with the potential to induce highly specific T-cell and antibody immune responses, also providing protective immunity with long-lasting immunologic memory against SARS-CoV-2 and other pandemic threats.
Managing director Ong Choon Lui said the partnership reaffirmed Ii-Key's technological potential to develop safe and effective vaccines.
“The involvement of China’s state-owned fund and cooperation at the highest government level through the China CDC increases the likelihood of success of vaccine commercialisation efforts,” he said.
Bintai Kinden said its subsidiary, Bintai Healthcare Sdn Bhd, had signed an agreement with Generex and its subsidiary, NuGenerex Immuco-Oncology Inc in October for the distribution and licensing of their Covid-19 vaccine in Malaysia.
The agreement granted Bintai Healthcare exclusive rights to distribute, sell, and commercialise the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand, and Vietnam.
“It will also have the right of first refusal to commercially exploit the vaccine within New Zealand, Australia and the global halal market,” it added.
China CDC is a governmental and national-level technical organisation specialising in disease control and prevention and public health, while Beijing Guoxin Haixiang is a limited partnership established to fund the research and development efforts of the partnership.
Meanwhile, Beijing Youfeng, also known as the China High-Tech Industrialisation Research Society Public Health Working Committee, provides development strategy consulting and design, project implementation, and management. – Bernama, November 5, 2020
